Percentage of plasma and PBMC specimens with detectable EBV DNA among patients with no EBV⁺ disease, grouped by the clinical setting in which EBV DNA testing was performed. (A) Patients with no EBV⁺ disease (n = 1419). (B) Transplant patients with no EBV⁺ disease (n = 562). AIHA, autoimmune hemolytic anemia; ITP, immune thrombocytopenic purpura; LPD, lymphoproliferative disorder.